je.st
news
Myriad Genetics Upgraded by Credit Suisse to "Neutral"
2014-02-09 03:19:34| Biotech - Topix.net
The firm currently has a $29.00 target price on the stock. Credit Suisse's price objective indicates a potential downside of 10.02% from the stock's previous close.
Tags: credit
suisse
neutral
genetics
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|